This is a curated selection of articles, which might be of importance for members of the NCRG. Prof. Mollnes regularly screens through newly published articles in order to provide his scholars an update. Therefore, this selection is highly selective, non all-embracing and might omit likewise important articles! 

In March Prof. Mollnes has provided an extensive article selection (61 articles!) – use the Corona inflicted home-office time to read through them!

1. Eculizumab and Beyond: The Past, Present, and Future of Complement Therapeutics.
   Patriquin CJ, Kuo KHM.
2. Complement dysregulation in the central nervous system during development and disease.
   Lee JD, Coulthard LG, Woodruff TM.
3. Complement dysregulation in glomerulonephritis.
   Kaartinen K, Safa A, Kotha S, Ratti G, Meri S.
4. CRIg plays an essential role in intravascular clearance of bloodborne parasites by interacting with complement.
   Liu G, Fu Y, Yosri M, Chen Y, Sun P, Xu J, Zhang M, Sun D, Strickland AB, Mackey ZB, Shi M.
5. Complement activation and regulation in rheumatic disease.
   Dijkstra DJ, Joeloemsingh JV, Bajema IM, Trouw LA.
6. Prognostic utility of ADAMTS13 activity for the atypical hemolytic uremic syndrome (aHUS) and comparison of complement serology between aHUS and thrombotic thrombocytopenic purpura.
   Oh J, Oh D, Lee SJ, Kim JO, Kim NK, Chong SY, Huh JY, Baker RI; Korean TTP Registry
7. Complement alternative pathway in ANCA-associated vasculitis: Two decades from bench to bedside.
   Brilland B, Garnier AS, Chevailler A, Jeannin P, Subra JF, Augusto JF
8. Blocking Complement Factor B Activation Reduces Renal Injury and Inflammation in a Rat Brain Death Model.
   Jager NM, van Zanden JE, Subías M, Leuvenink HGD, Daha MR, Rodríguez de Córdoba S, Poppelaars F, Seelen MA.
9. Urinary Properdin and sC5b-9 Are Independently Associated With Increased Risk for Graft Failure in Renal Transplant Recipients.
   Lammerts RGM, Eisenga MF, Alyami M, Daha MR, Seelen MA, Pol RA, van den Born J, Sanders JS, Bakker SJL, Berger SP.
10. Regulation of the complement system and immunological tolerance in pregnancy.
    Teirilä L, Heikkinen-Eloranta J, Kotimaa J, Meri S, Lokki AI.
11. Identification of Adipsin as a Novel Prognostic Biomarker in Patients With Coronary Artery Disease.
    Ohtsuki T, Satoh K, Shimizu T, Ikeda S, Kikuchi N, Satoh T, Kurosawa R, Nogi M, Sunamura S, Yaoita N, Omura J, Aoki T, Tatebe S, Sugimura K, Takahashi J, Miyata S, Shimokawa H.
12. The alternative complement pathway activation product Ba as a marker for transplant-associated thrombotic microangiopathy.
    Sartain S, Shubert S, Wu MF, Wang T, Martinez C.
13. Lanadelumab for the prevention of attacks in hereditary angioedema.
    Valerieva A, Senter R, Wu MA, Zanichelli A, Cicardi M.
14. Pregnancy Prolongation After Eculizumab Use in Early-Onset Preeclampsia.
    Lu AB, Lazarus B, Rolnik DL, Palmer KR.
15. Prognostic utility of ADAMTS13 activity for the atypical hemolytic uremic syndrome (aHUS) and comparison of complement serology between aHUS and thrombotic thrombocytopenic purpura.
    Oh J, Oh D, Lee SJ, Kim JO, Kim NK, Chong SY, Huh JY, Baker RI; Korean TTP Registry Investigators
16. Platelet function in patients with septic shock.
    Laursen MA, Larsen JB, Larsen KM, Hvas AM.
17. Recurrent Demyelinating Episodes as Sole Manifestation of Inherited CD59 Deficiency.
    Solmaz I, Aytekin ES, Çağdaş D, Tan C, Tezcan I, Gocmen R, Haliloglu G, Anlar B.
18. Impact of High-Dose Intravenous Vitamin C for Treatment of Sepsis on Point-of-Care Blood Glucose Readings.
    Howell AP, Parrett JL, Malcom DR.
19. Vitamin C therapy for patients with sepsis or septic shock: a protocol for a systematic review and a network meta-analysis.
    Fujii T, Belletti A, Carr A, Furukawa TA, Luethi N, Putzu A, Sartini C, Salanti G, Tsujimoto Y, Udy AA, Young PJ, Bellomo R.
20. Pseudoginsenoside-F11 Accelerates Microglial Phagocytosis of Myelin Debris and Attenuates Cerebral Ischemic Injury Through Complement Receptor 3.
    Liu Y, Wu C, Hou Z, Fu X, Yuan L, Sun S, Zhang H, Yang D, Yao X, Yang J.
21. Current and Future Approaches for Monitoring Responses to Anti-complement Therapeutics.
    Mohebnasab M, Eriksson O, Persson B, Sandholm K, Mohlin C, Huber-Lang M, Keating BJ, Ekdahl KN, Nilsson B.
22. Selective and marked decrease of complement receptor C5aR2 in human thoracic aortic aneurysms: a dysregulation with potential inflammatory effects.
    Holt M, Seim BE, Øgaard J, Olsen MB, Woldbæk PR, Kvitting JE, Aukrust P, Yndestad A, Mollnes TE, Nilsson PH, Louwe MC, Ranheim T.
23. Complement C5 Contributes to Brain Injury After Subarachnoid Hemorrhage.
    van Dijk BJ, Meijers JCM, Kloek AT, Knaup VL, Rinkel GJE, Morgan BP, van der Kamp MJ, Osuka K, Aronica E, Ruigrok YM, van de Beek D, Brouwer M, Pekna M, Hol EM, Vergouwen MDI.
24. C5aR agonist enhances phagocytosis of fibrillar and non-fibrillar Aβ amyloid and preserves memory in a mouse model of familial Alzheimer’s disease.
    Panayiotou E, Fella E, Andreou S, Papacharalambous R, Gerasimou P, Costeas P, Angeli S, Kousiappa I, Papacostas S, Kyriakides T.
25. Therapeutic targeting of the complement system.
    Ricklin D, Mastellos DC, Lambris JD.
26. Intracortical Administration of the Complement C3 Receptor Antagonist Trifluoroacetate Modulates Microglia Reaction after Brain Injury.
    Surugiu R, Catalin B, Dumbrava D, Gresita A, Olaru DG, Hermann DM, Popa-Wagner A.
27. Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS.
    Chaturvedi S, Braunstein EM, Yuan X, Yu J, Alexander A, Chen H, Gavriilaki E, Alluri R, Streiff MB, Petri M, Crowther MA, McCrae KR, Brodsky RA.
28. Binding of von Willebrand Factor to Complement C1q Decreases the Phagocytosis of Cholesterol Crystals and Subsequent IL-1 Secretion in Macrophages.
    Donat C, Thanei S, Trendelenburg M.
29. Three-Year Outcomes of a Randomized, Double-Blind, Placebo-Controlled Study Assessing Safety and Efficacy of C1 Esterase Inhibitor for Prevention of Delayed Graft Function in Deceased Donor Kidney Transplant Recipients.
    Huang E, Vo A, Choi J, Ammerman N, Lim K, Sethi S, Kim I, Kumar S, Najjar R, Peng A, Jordan SC.
30. Successful treatment of a PNH patient non-responsive to eculizumab with the novel complement C5 inhibitor coversin (nomacopan).
    Schols S, Nunn MA, Mackie I, Weston-Davies W, Nishimura JI, Kanakura Y, Blijlevens N, Muus P, Langemeijer S.
31. Properdin: A Novel Target for Neuroprotection in Neonatal Hypoxic-Ischemic Brain Injury.
    Sisa C, Agha-Shah Q, Sanghera B, Carno A, Stover C, Hristova M.
32. Intravitreal Therapy Against the Complement Factor C5 Prevents Retinal Degeneration in an Experimental Autoimmune Glaucoma Model.
    Reinehr S, Gomes SC, Gassel CJ, Asaad MA, Stute G, Schargus M, Dick HB, Joachim SC.
33. Complement Receptor 1 (CR1/CD35)-expressing retinal pigment epithelial cells as a potential therapy for age-related macular degeneration.
    Simmons KT, Mazzilli JL, Mueller-Ortiz SL, Domozhirov AY, Garcia CA, Zsigmond EM, Wetsel RA.
34. ACE inhibitor-mediated angioedema.
    Montinaro V, Cicardi M.
35. Impaired control of the contact system in hereditary angioedema with normal C1-inhibitor.
    Bova M, Suffritti C, Bafunno V, Loffredo S, Cordisco G, Del Giacco S, De Pasquale TMA, Firinu D, Margaglione M, Montinaro V, Petraroli A, Radice A, Brussino L, Zanichelli A, Zoli A, Cicardi M.
36. Study of Biocompatibility of Membranes in Online Hemodiafiltration.
    Ojeda R, Arias-Guillén M, Gómez M, Vera M, Fontseré N, Rodas L, Filella X, Reverter JC, Lozano F, Villamor N, Maduell F.
37. Formation of Protein Corona on Nanoparticle Affects Different Complement Activation Pathways Mediated by C1q.
    Ding T, Sun J.
38. An inhibitor of complement C5 provides structural insights into activation.
    Reichhardt MP, Johnson S, Tang T, Morgan T, Tebeka N, Popitsch N, Deme JC, Jore MM, Lea SM.
39. Diagnostic and Risk Factors for Complement Defects in Hypertensive Emergency and Thrombotic Microangiopathy.
    Timmermans SAMEG, Wérion A, Damoiseaux JGMC, Morelle J, Reutelingsperger CP, van Paassen P.
40. Use of the terminal complement inhibitor eculizumab in paediatric heart transplant recipients.
    Law YM, Nandi D, Molina K, Gambetta K, Daly KP, Das B.t and sepsis – this s a curious story, but since it is published in SHOCK, I forard it. A very peculuar assay for C3 ctivation – but Per knows everything about  this – so if you have qustions; just mail him.
41. Circulating Complement C3-Alpha Chain Levels Predict Survival of Septic Shock Patients.
    Cheng TH, Puskarich M, Li X, Fang Z, Xu F, Chen Y, Jiang XC, Worah S, Jones AE, Zhang M.
42. Platelet thrombus formation in eHUS is prevented by anti-MBL2.
    Kushak RI, Boyle DC, Rosales IA, Ingelfinger JR, Stahl GL, Ozaki M, Colvin RB, Grabowski EF.
43. The role of anti-complement factor H antibodies in the development of atypical haemolytic uremic syndrome: a possible contribution to abnormality of platelet function.
    Fujisawa M, Yasumoto A, Kato H, Sugawara Y, Yoshida Y, Yatomi Y, Nangaku M.
44. Complement factor H contributes to mortality in humans and mice with bacterial meningitis.
    Kasanmoentalib ES, Valls Serón M, Engelen-Lee JY, Tanck MW, Pouw RB, van Mierlo G, Wouters D, Pickering MC, van der Ende A, Kuijpers TW, Brouwer MC, van de Beek D.
45. Targeted Complement Inhibition at Synapses Prevents Microglial Synaptic Engulfment and Synapse Loss in Demyelinating Disease.
    Werneburg S, Jung J, Kunjamma RB, Ha SK, Luciano NJ, Willis CM, Gao G, Biscola NP, Havton LA, Crocker SJ, Popko B, Reich DS, Schafer DP.
46. Complement fragments are biomarkers of antibody-mediated endothelial injury.
    Stites E, Renner B, Laskowski J, Le Quintrec M, You Z, Freed B, Cooper J, Jalal D, Thurman JM.
47. Eculizumab Safety: Five-Year Experience From the Global Atypical Hemolytic Uremic Syndrome Registry.
    Rondeau E, Cataland SR, Al-Dakkak I, Miller B, Webb NJA, Landau D.
48. Complement activation by autoantigen recognition in the growth process of benign prostatic hyperplasia.
    Hata J, Machida T, Matsuoka K, Hoshi S, Akaihata H, Hiraki H, Suzuki T, Ogawa S, Kataoka M, Haga N, Ishibashi K, Homma Y, Sekine H, Kojima Y.
49. Predictive value of mesangial C3 and C4d deposition in IgA nephropathy.
    Nam KH, Joo YS, Lee C, Lee S, Kim J, Yun HR, Park JT, Chang TI, Ryu DR, Yoo TH, Chin HJ, Kang SW, Jeong HJ, Lim BJ, Han SH; Korean GlomeruloNEphritis sTudy (KoGNET) Group.
50. Microglia exacerbate white matter injury via complement C3/C3aR pathway after hypoperfusion.
    Zhang LY, Pan J, Mamtilahun M, Zhu Y, Wang L, Venkatesh A, Shi R, Tu X, Jin K, Wang Y, Zhang Z, Yang GY.
51. Eculizumab for Severe Thrombotic Microangiopathy Secondary to Surgical Invasive Stress and Bleeding.
    Fujita Y, Terashita M, Yazawa M, Yamasaki Y, Imamura T, Kibayashi J, Sawai T, Hidaka Y, Ohtani K, Inoue N, Shibagaki Y.
52. Inhibition of osteoclast activity by complement regulation with DF3016A, a novel small-molecular-weight C5aR inhibitor.
    D’Angelo R, Mangini M, Fonderico J, Fulle S, Mayo E, Aramini A, Mariggiò S.
53. Potent Thiophene Antagonists of Human Complement C3a Receptor with Anti-Inflammatory Activity.
    Rowley JA, Reid RC, Poon EKY, Wu KC, Lim J, Lohman RJ, Hamidon JK, Yau MK, Halili MA, Durek T, Iyer A, Fairlie DP.
54. Complement-Mediated Events in Alzheimer’s Disease: Mechanisms and Potential Therapeutic Targets.
    Tenner AJ.
55. Targeted donor complement blockade after brain death prevents delayed graft function in a nonhuman primate model of kidney transplantation.
    Danobeitia JS, Zens TJ, Chlebeck PJ, Zitur LJ, Reyes JA, Eerhart MJ, Coonen J, Capuano S, D’Alessandro AM, Torrealba JR, Burguete D, Brunner K, Van Amersfoort E, Ponstein Y, Van Kooten C, Jankowska-Gan E, Burlingham W, Sullivan J, Djamali A, Pozniak M, Yankol Y, Fernandez LA.
56. Labile Heme Aggravates Renal Inflammation and Complement Activation After Ischemia Reperfusion Injury.
    Wang L, Vijayan V, Jang MS, Thorenz A, Greite R, Rong S, Chen R, Shushakova N, Tudorache I, Derlin K, Pradhan P, Madyaningrana K, Madrahimov N, Bräsen JH, Lichtinghagen R, van Kooten C, Huber-Lang M, Haller H, Immenschuh S, Gueler F.
57. Targeting the Complement Alternative Pathway Permits Graft Versus Leukemia Activity while Preventing Graft Versus Host Disease.
    Nguyen H, Alawieh A, Bastian D, Kuril S, Dai M, Daenthanasanmak A, Zhang M, Iamsawat S, Schutt SD, Wu Y, Sleiman MM, Shetty A, Atkinson C, Sun S, Varela JC, Tomlinson S, Yu XZ.
58. Complement Activation in Human Sepsis is Related to Sepsis-Induced Disseminated Intravascular Coagulation.
    Abe T, Kubo K, Izumoto S, Shimazu S, Goan A, Tanaka T, Koroki T, Saito K, Kawana R, Ochiai H.
59. Second-Generation C5 Inhibitors for Paroxysmal Nocturnal Hemoglobinuria.
    Fattizzo B, Kulasekararaj AG.
60. l-Fucose prevention of renal ischaemia/reperfusion injury in Mice.
    Howard MC, Nauser CL, Farrar CA, Wallis R, Sacks SH.
61. The First Case of Ischemia-Free Kidney Transplantation in Humans.
    He X, Chen G, Zhu Z, Zhang Z, Yuan X, Han M, Zhao Q, Zheng Y, Tang Y, Huang S, Wang L, van Leeuwen OB, Wang X, Chen C, Mo L, Jiao X, Li X, Wang C, Huang J, Cui J, Guo Z.